Zacks Research Has Positive Outlook for Amarin Q3 Earnings

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Zacks Research raised their Q3 2025 EPS estimates for shares of Amarin in a research report issued on Wednesday, June 25th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.60) per share for the quarter, up from their previous estimate of ($0.74). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.59) EPS, Q1 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.67) EPS.

Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative return on equity of 17.21%.

A number of other research firms have also issued reports on AMRN. The Goldman Sachs Group raised their price target on Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a report on Wednesday, June 25th. Wall Street Zen raised Amarin from a "sell" rating to a "hold" rating in a report on Thursday, May 8th.

Amarin Stock Down 2.0%

AMRN traded down $0.34 during trading on Friday, hitting $16.48. 79,664 shares of the stock were exchanged, compared to its average volume of 81,913. Amarin has a 1-year low of $7.08 and a 1-year high of $18.68. The stock has a fifty day moving average price of $12.05 and a two-hundred day moving average price of $10.80. The firm has a market capitalization of $341.20 million, a P/E ratio of -4.52 and a beta of 0.82.

Institutional Trading of Amarin

Hedge funds have recently modified their holdings of the business. Banque Cantonale Vaudoise acquired a new stake in shares of Amarin during the 1st quarter valued at approximately $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Amarin in the fourth quarter valued at approximately $36,000. Kornitzer Capital Management Inc. KS grew its stake in shares of Amarin by 4.0% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 3,400 shares during the period. Generation Capital Management LLC purchased a new stake in shares of Amarin during the 4th quarter worth about $50,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Amarin in the fourth quarter worth $55,000. 22.25% of the stock is owned by institutional investors and hedge funds.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.